| Name | Title | Contact Details |
|---|
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia
Tjoapack is a contract packaging organisation which specialises in developing innovative primary & secondary packaging solutions for the pharma supply chain.
Avante is a single source provider of surgical, diagnostic imaging and radiation oncology equipment. Sales, service, repair, parts, installation.
Pharmacyvillage.com is a Norman, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stallergenes Greer is a global biopharmaceutical company specializing in the diagnosis and treatment of respiratory allergies through the development and commercialization of Allergy Immunotherapy products and services. Our purpose is to enable people with allergies to live normal lives. With more than 1,400 employees worldwide, a presence in 75 countries, and manufacturing facilities in both Europe and the United States, Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France). With complementary strengths, joint heritage and reputations, Stallergenes Greer is driving a continuing leadership in allergy immunotherapy.